Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 21.81 USD 0.14% Market Closed
Market Cap: 13.8B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GMAB stock under the Base Case scenario is 39.78 USD. Compared to the current market price of 21.81 USD, Genmab A/S is Undervalued by 45%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GMAB Relative Value
Base Case
39.78 USD
Undervaluation 45%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11.5
P/S
P/S
Price to Sales
11.5
vs History
68
vs Industry
66
Median 3Y
11.5
Median 5Y
14.8
Industry
6.9
Forward
3.6
More Details
38.5
P/E
P/E
Price to Earnings
38.5
vs History
41
vs Industry
10
Median 3Y
36.8
Median 5Y
36.8
Industry
23
Forward
13.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
13
Median 3Y
39.8
Median 5Y
37.8
Industry
19.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
11
Median 3Y
42
Median 5Y
40.6
Industry
22.8
More Details
17.3
P/B
P/B
Price to Book Value
17.3
vs History
6
vs Industry
38
Median 3Y
6.3
Median 5Y
7.2
Industry
2.6
More Details
11.1
EV/S
EV/S
Enterprise Value to Sales
11.1
vs History
61
vs Industry
61
Median 3Y
10.6
Median 5Y
13
Industry
7.4
Forward
3.5
More Details
11.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.6
vs History
23
vs Industry
64
Median 3Y
6.5
Median 5Y
0
Industry
9.3
More Details
34.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
34.6
vs History
44
vs Industry
12
Median 3Y
31.2
Median 5Y
31.2
Industry
4.1
Forward
10.2
More Details
35.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
35.7
vs History
42
vs Industry
10
Median 3Y
32.2
Median 5Y
32.2
Industry
4.1
Forward
11.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
14
Median 3Y
36.6
Median 5Y
33.3
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
10
Median 3Y
37.9
Median 5Y
35.2
Industry
3.6
More Details
26.3
EV/IC
EV/IC
Enterprise Value to IC
26.3
vs History
34
vs Industry
42
Median 3Y
19.1
Median 5Y
24.1
Industry
4.7
More Details

Multiples Across Competitors

GMAB Competitors Multiples
Genmab A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Genmab A/S
NASDAQ:GMAB
91.4B USD 11.5 38.5 34.6 35.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 627 281.5 -164 578.3 -199 850.6 -197 570
US
Abbvie Inc
NYSE:ABBV
331.1B USD 5.8 79.7 15.2 22.5
US
Amgen Inc
NASDAQ:AMGN
154.4B USD 4.5 26 14.1 23.2
US
Gilead Sciences Inc
NASDAQ:GILD
137.5B USD 4.8 23.1 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114B USD 10.3 -115.3 24.5 25.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 034.5 -519.1 -565.3 -550.2
AU
CSL Ltd
ASX:CSL
117.1B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
52.3B USD 3.7 11.6 10.2 11.5
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60.1 -64.7 -58.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.1B USD 17.1 -148.8 -666.4 -334
P/S Multiple
Revenue Growth P/S to Growth
DK
Genmab A/S
NASDAQ:GMAB
Average P/S: 3 148 127.1
11.5
117%
0.1
FR
Pharnext SCA
OTC:PNEXF
34 627 281.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 034.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.7
5%
0.7
US
S
Seagen Inc
F:SGT
19.6
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
DK
Genmab A/S
NASDAQ:GMAB
Average P/E: 34.4
38.5
104%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 578.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
79.7
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.1 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -148.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
NASDAQ:GMAB
Average EV/EBITDA: 18
34.6
126%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 850.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
11%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -666.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Genmab A/S
NASDAQ:GMAB
Average EV/EBIT: 22
35.7
121%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 570 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.2
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -334 N/A N/A

See Also

Summary
GMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
GMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GMAB stock valuation using valuation multiples.
Wall Street Estimates
GMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 259,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.